Nova Anchora
San Francisco · Founded 2021
- Headquarters
- San Francisco, California
- Founded
- 2021
- Business Model
- B2B
- Website
- novaanchora.com
- Last Round
- SeedApr 2025
- Rounds
- 1
About
Nova Anchora is a biopharmaceutical company advancing a corrective protein therapy for dystrophic epidermolysis bullosa (DEB), a severe rare genetic skin disease. Built on foundational technology developed by Dr. Peter Marinkovich of Stanford Medicine and licensed from Stanford University, the company is developing NvA-011, a recombinant type VII pro-collagen therapy designed for topical application, which received FDA orphan drug designation in 2024.
Summary
Nova Anchora is a Biotech company based in San Francisco, founded in 2021. Its most recent funding was a Seed round in Apr 2025. Investors include Viking Global.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Apr 2025
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biopharmaceutical services company
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Specialty pharmaceutical company
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...